LUNAC Therapeutics Overview

  • Founded
  • 2018
Founded
  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $4.05M
Latest Deal Amount
  • Investors
  • 3

LUNAC Therapeutics General Information

Description

Developer of advanced oral anticoagulant designed to treat and prevent life-threatening thrombotic events. The company's advanced oral anticoagulant minimizes the bleeding risk, enabling healthcare providers to handle high-risk patients with safe dose escalation.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Secretariat, Ec Stoner Building
  • Woodhouse Lane
  • Leeds LS2 9JT
  • England, United Kingdom

LUNAC Therapeutics Timeline

20192020
Date FoundedFinancing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

LUNAC Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant 02-Dec-2019 $4.05M 00.00 Completed Generating Revenue
1. Early Stage VC (Series A) 14-Nov-2019 00.00 00.00 00.000 Completed Generating Revenue
To view LUNAC Therapeutics’s complete valuation and funding history, request access »

LUNAC Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000 00.000000 00 000.00 000.00 00 000.00 00.00
To view LUNAC Therapeutics’s complete cap table history, request access »

LUNAC Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Helen Philippou Scientific Co-Founder & Board Member
Richard Foster Scientific Co-Founder
To view LUNAC Therapeutics’s complete executive team members history, request access »

LUNAC Therapeutics Board Members (6)

Name Representing Role Since
Helen Philippou LUNAC Therapeutics Scientific Co-Founder & Board Member 000 0000
Mary Canning Ph.D Epidarex Capital Board Member 000 0000
Mervyn Turner Ph.D Self Chairman 000 0000
Peter Finan Ph.D Epidarex Capital Board Member 000 0000
Sarah Jarmin Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

LUNAC Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
UK Government's Biomedical Catalyst funding Government 000 0000 000000 0
Epidarex Capital Venture Capital Minority 000 0000 000000 0
University of Leeds Endowment Limited Partner Minority 000 0000 000000 0
To view LUNAC Therapeutics’s complete investors history, request access »